WO2005097830A3 - Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds - Google Patents

Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds Download PDF

Info

Publication number
WO2005097830A3
WO2005097830A3 PCT/DK2005/000240 DK2005000240W WO2005097830A3 WO 2005097830 A3 WO2005097830 A3 WO 2005097830A3 DK 2005000240 W DK2005000240 W DK 2005000240W WO 2005097830 A3 WO2005097830 A3 WO 2005097830A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
binding members
individual
relates
isolated
Prior art date
Application number
PCT/DK2005/000240
Other languages
French (fr)
Other versions
WO2005097830A2 (en
Inventor
Christian Hansen
Original Assignee
Aditech Pharma Ab
Christian Hansen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aditech Pharma Ab, Christian Hansen filed Critical Aditech Pharma Ab
Publication of WO2005097830A2 publication Critical patent/WO2005097830A2/en
Publication of WO2005097830A3 publication Critical patent/WO2005097830A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising isolated binding members, such as antibodies and/or affibodies, capable of specifically binding a secretagogue, such as ghrelin or a ghrelin-like compound. In another aspect of the present invention, a kit and method are provided for detecting a disorder in appetite regulation in an individual. The present invention also relates to use of the isolated binding members disclosed herein for the production of a pharmaceutical composition, for the treatment of an individual in need thereof. There is further provided herein a method for treatment of an individual in need thereof, comprising administering to said individual an effective amount of one or more of the pharmaceutical compositions of the present invention. The present invention further relates to isolated nucleic acid molecules encoding at least a part of the binding members disclosed herein and vectors comprising said nucleic acid molecules. Host cells comprising said nucleic acids are also disclosed, and the present invention further relates to a cell line engineered to express one or more of the binding members disclosed herein. Furthermore, the present invention relates to cosmetic compositions comprising the binding members of the present invention and cosmetic methods using said cosmetic composition.
PCT/DK2005/000240 2004-04-07 2005-04-07 Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds WO2005097830A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200400571 2004-04-07
DKPA200400571 2004-04-07

Publications (2)

Publication Number Publication Date
WO2005097830A2 WO2005097830A2 (en) 2005-10-20
WO2005097830A3 true WO2005097830A3 (en) 2005-12-22

Family

ID=34964231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000240 WO2005097830A2 (en) 2004-04-07 2005-04-07 Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds

Country Status (1)

Country Link
WO (1) WO2005097830A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119800A1 (en) * 2012-02-07 2013-08-15 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2014144231A1 (en) 2013-03-15 2014-09-18 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
WO2016138099A1 (en) 2015-02-24 2016-09-01 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017606A1 (en) * 1991-04-01 1992-10-15 Brigham And Women's Hospital Microassay system and neutrophil derived secretagogue
WO2001087335A2 (en) * 2000-05-17 2001-11-22 Eli Lilly And Company Method for selectively inhibiting ghrelin action
EP1197496A1 (en) * 1999-07-23 2002-04-17 Kenji Kangawa Novel peptides
WO2004024183A1 (en) * 2002-09-12 2004-03-25 Pharmexa A/S Immunization against autologous ghrelin
WO2005016951A2 (en) * 2003-06-04 2005-02-24 Eli Lilly And Company Anti-ghrelin fab antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017606A1 (en) * 1991-04-01 1992-10-15 Brigham And Women's Hospital Microassay system and neutrophil derived secretagogue
EP1197496A1 (en) * 1999-07-23 2002-04-17 Kenji Kangawa Novel peptides
WO2001087335A2 (en) * 2000-05-17 2001-11-22 Eli Lilly And Company Method for selectively inhibiting ghrelin action
WO2004024183A1 (en) * 2002-09-12 2004-03-25 Pharmexa A/S Immunization against autologous ghrelin
WO2005016951A2 (en) * 2003-06-04 2005-02-24 Eli Lilly And Company Anti-ghrelin fab antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANANTH S ET AL: "Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 9, 1 May 1999 (1999-05-01), pages 2210 - 2216, XP002117563, ISSN: 0008-5472 *
MACARTHUR C K ET AL: "A PEPTIDE SECRETED BY HUMAN ALVEOLAR MACROPHAGES RELEASES NEUTROPHIL GRANULE CONTENTS", JOURNAL OF IMMUNOLOGY, vol. 139, no. 10, 1987, pages 3456 - 3462, XP002352742, ISSN: 0022-1767 *
SPERBER KIRK ET AL: "In vivo detection of a novel macrophage-derived protein involved in the regulation of mucus-like glycoconjugate secretion", AMERICAN REVIEW OF RESPIRATORY DISEASE, vol. 146, no. 6, 1992, pages 1589 - 1597, XP009056431, ISSN: 0003-0805 *
STILES J D ET AL: "Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, NEW YORK, NY, US, vol. 56, no. 4, April 1997 (1997-04-01), pages 435 - 439, XP002117561, ISSN: 0022-3069 *

Also Published As

Publication number Publication date
WO2005097830A2 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
CN101687915B8 (en) Cross-species-specific cd 3-epsilon binding domain
WO2005077042A3 (en) Albumin fusion proteins
WO2008033413A3 (en) Albumin fusion proteins
WO2005003296A3 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
EP2233497A3 (en) Amylin family peptides and methods for making and using them
EA200700408A1 (en) TRANSPORT PROTEIN FOR DELIVERY OF CHEMICAL COMPOUNDS IN NERVOUS CELLS
WO2006073839A3 (en) Acid fungal proteases
TNSN08064A1 (en) Albumin fusion proteins
NZ591415A (en) Haemophilus influenzae type B
EA201071323A1 (en) AXMI-115, AXMI-113, AXMI-005, AXMI-163, AXMI-184 INSECTICIDE PROTEINS AND METHODS OF THEIR APPLICATION
WO2005069762A3 (en) Bacillus licheniformis chromosome
MX348154B (en) IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF.
UA100682C2 (en) Antibody which neutralizes human cytomegalovirus (hcmv) and use thereof
WO2010037836A3 (en) Cross-species-specific psmaxcd3 bispecific single chain antibody
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2005100403A3 (en) Antibodies to erythropoietin receptor and uses thereof
MX2009005175A (en) Lingo binding molecules and pharmaceutical use thereof.
WO2008077945A3 (en) Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
AU2003220115A1 (en) Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
WO2006091094A3 (en) Hemoglobin overexpression in fungal fermentations
BRPI0412607A (en) method for enhancing the efficacy of biological reaction modifying proteins and resulting muteins
WO2005097830A3 (en) Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
WO2004100636A3 (en) Method for modifying transcription and/or translation in an organism
WO2005097831A3 (en) Uses of isolated binding members capable of binding specifically to secretagogues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (EPO FORM 1205A) DATED 19.12.2006

122 Ep: pct application non-entry in european phase